INVESTIGADORES
MASTAGLIA Silvina Rosana
artículos
Título:
Effect of time of administration of teriparatide on bone mineral density in glucocorticoid-induced osteoporosis
Autor/es:
MASTAGLIA S
Revista:
JOURNAL OF CLINICAL DENSITOMETRY
Editorial:
ELSEVIER SCIENCE INC
Referencias:
Lugar: Amsterdam; Año: 2017
ISSN:
1094-6950
Resumen:
Teriparatide (TPTD) [recombinant DNA origin human PTH (1-34)] is approved for the treatment of glucocorticoidinduced osteoporosis (GIO). There are reports of factors that affect response to TPTD in GIO treatment. This work describes the case of a 71-year old woman diagnosed with lupus nephropathy treated with 40mg/day of meprednisone, and who suffered multiple vertebral fractures. Despite treatment with a single 5mg-dose of zoledronic acid, she continued to have vertebral fractures. Treatment with 20µg/day of subcutaneous (s.c.) TPTD (PTH1-34,Forteo; Eli Lilly Co., Indianapolis, IN, United States) was initiated. Nine months after onset of treatment, BMD assessment showed a 5% decrease in lumbar spine (LS) BMD. Factors potentially affecting results were analyzed.The patient reported injecting TPTD at night; and she was instructed to inject TPTD in the morning before breakfast. After changing time of TPTD administration and 22 months after initiating treatment, BMD assessment was repeatedand showed 18% increase at LS, and no new vertebral fractures. Time of TPTD administration might affect response to TPTD in GIO treatment.